Benign and Malignant Tumors of the Brain

  • Elizabeth B. Claus
  • Joseph Piepmeier

Abstract

Data from the National Cancer Institute (NCI) indicate that approximately 17,600 individuals within the United States were expected to be diagnosed with a first primary cancer of the central nervous system (CNS) in 1997, of whom approximately 15% would be aged 70 years or more.1 Most of these individuals would die from their disease, with overall 5-year survival rates estimated to be approximately 30%.1 In addition, up to 100,000 Americans are diagnosed each year with metastatic brain lesions, most of whom are elderly patients. Although improved technology and treatment modalities have led to increased detection of brain lesions and better control of systemic primary malignancies, little progress has been made with respect to survival and identification of risk factors in individuals diagnosed with these lesions. The conflict between these two is particularly important in the elderly, given that Americans over the age of 70 years now make up the fastest growing portion of the U.S. population.2 This chapter provides a review and discussion of options for the detection, treatment, and outcome of elderly patients diagnosed with tumors of the brain.

Keywords

Elderly Patient Brain Tumor Malignant Glioma Primary Brain Tumor Whole Brain Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Randall T. Demographers ponder the aging of the aged and await unprecedented looming elder boom. JAMA 1994;269: 2331–2332.CrossRefGoogle Scholar
  3. 3.
    Velema JP, Percy CL. Age curves of central nervous system tumors in adults: variation of shape by histologic subtype. J Natl Cancer Inst 1987;79:623–629.PubMedGoogle Scholar
  4. 4.
    Polednak AP, Flannery JT. Brain, other central nervous system, and eye cancer. Cancer 1995;75:330–337.PubMedCrossRefGoogle Scholar
  5. 5.
    Roush GC, Holford TR, Schymura MJ. Cancer Risk and Incidence Trends: the Connecticut Perspective. New York: Hemisphere, 1987.Google Scholar
  6. 6.
    Polednek AR Time trends in incidence of brain and central nervous system cancer in Connecticut. J Natl Cancer Inst 1991;83:1679–1681.CrossRefGoogle Scholar
  7. 7.
    Modan B, Wagener DK, Feldman JJ, Rosenberg HM, Feinleib BK. Increased mortality from brain tumors: a combined outcome of diagnostic technology and changes in attitude toward the elderly. Am J Epidemiol 1992;135:1349–1357.PubMedGoogle Scholar
  8. 8.
    Grieg NH, Ries LG, Yancik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 1990;82:1621–1624.CrossRefGoogle Scholar
  9. 9.
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;332:494–500.CrossRefGoogle Scholar
  10. 10.
    Wrensch M, Bondy M, Wiencke J, Yost M. Environmental risk factors for malignant brain tumors: a review. J Neurooncol 1993;17:47–64.PubMedCrossRefGoogle Scholar
  11. 11.
    Larsen NS. Brain tumor incidence rising; researchers ask why. J Natl Cancet Inst 1993;88:1024–1025.CrossRefGoogle Scholar
  12. 12.
    Kallio M. Therapy and survival of adult patients with intracranial glioma in a defined population. Acta Neurol Scand 1990;81:541–549.PubMedCrossRefGoogle Scholar
  13. 13.
    Laws ER Jr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 1984;61:665–673.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang CH, Horton J, Schoenfeld, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 1983;52:997–1007.PubMedCrossRefGoogle Scholar
  15. 15.
    Ampil F, Fowler M, Kim K. Intracranial astrocytoma in elderly patients. J Neurooncol 1992;12:125–130.PubMedCrossRefGoogle Scholar
  16. 16.
    Tomika T, Raimondi AJ. Brain tumors in the elderly. JAMA 1981;246:53–55.CrossRefGoogle Scholar
  17. 17.
    Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol 1991;36:106–111.PubMedCrossRefGoogle Scholar
  18. 18.
    Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994;34:62–67.PubMedCrossRefGoogle Scholar
  19. 19.
    Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults: the prognostic importance of resection and prior low grade glioma. J Neurosurg 1989; 71:487–493.PubMedCrossRefGoogle Scholar
  20. 20.
    Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987;21:201–206.PubMedCrossRefGoogle Scholar
  21. 21.
    Peschel RE, Wilson L, Haffty B, Papadopoulos D, Rosenzweig K, Feltes M. The effect of advanced age on the efficacy of radiation therapy for early breast cancer, local prostate cancer and grade III-IV gliomas. Intl J Radiat Oncol 1993;26:539–544.CrossRefGoogle Scholar
  22. 22.
    Newall J, Ransohoff J, Kaplan B. Glioblastoma in the older patient: how long a course of radiotherapy is necessary? J Neurooncol 1988;6:325–327.PubMedCrossRefGoogle Scholar
  23. 23.
    Kleinberg L, Slick T, Enger C, Grossman S, Brem H, Wharam MD Jr. Short course therapy is an appropriate option for most malignant glioma patients. Intl J Radiat Oncol 1997;38:31–36.CrossRefGoogle Scholar
  24. 24.
    Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978;49:333–343.PubMedCrossRefGoogle Scholar
  25. 25.
    Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303: 1323–1329.PubMedCrossRefGoogle Scholar
  26. 26.
    Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008–1012.PubMedCrossRefGoogle Scholar
  27. 27.
    Graham K, Caird FI. High-dose steroid therapy of intracranial tumour in the elderly. Age Ageing 1978;7:146–150.PubMedCrossRefGoogle Scholar
  28. 28.
    Wrensch M, Lee M, Miike R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 1997;145:581–593.PubMedCrossRefGoogle Scholar
  29. 29.
    Bello MJ, de Campos JM, Kusak ME, et al. Molecular analysis of genomic abnormalities in human gliomas. Cancer Genet Cytogenet 1994;73:122–129.PubMedCrossRefGoogle Scholar
  30. 30.
    Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6: 217–223.PubMedCrossRefGoogle Scholar
  31. 31.
    Von Deimling A, Louis DN, Wiestier OD. Molecular pathways in the formation of gliomas: review. Glia 1995;15:328–338.CrossRefGoogle Scholar
  32. 32.
    Hall WA, Cho KH, Lee A, Gerbi BJ, Lee CK. Solitary brain metastases: surgery, stereotactic radiosurgery and/or radiation therapy? Presented at the annual meeting of the Congress of Neurological Surgeons, Montreal 1997.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Elizabeth B. Claus
  • Joseph Piepmeier

There are no affiliations available

Personalised recommendations